MOB Moberg Pharma AB (publ)

STO · SE · Healthcare · Drug Manufacturers - Specialty & Generic · mobergpharma.se

11.14SEK+1.27%Mkt Cap: 50.27M $P/E: —3d ago

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly k…

Industry Peers

Drug Manufacturers - Specialty & Generic

Screen all

MRK

MERCK Kommanditgesellschaft auf Aktien

$64.70BUSDP/E 25.1

TAK

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$57.06BUSD

TEVA

Teva Pharmaceutical Industries Limited Ordinary Shares

$46.10BUSDP/E 65.9

HLN

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

$38.70BUSDP/E 18.3

ZTS

Zoetis Inc. Class A Common Stock

United Therapeutics Corporation - Common Stock

$23.23BUSDP/E 19.4

VTRS

Viatris Inc. - Common Stock

$20.22BUSD

SOBI

Swedish Orphan Biovitrum AB

$14.24BUSDP/E 109.4

NBIX

Neurocrine Biosciences, Inc. - Common Stock

Elanco Animal Health Incorporated Common Stock

$11.06BUSD

RDY

Dr. Reddy's Laboratories Ltd Common Stock

Amneal Pharmaceuticals, Inc. - Class A Common Stock

$7.07BUSDP/E 42.3

ALKS

Alkermes plc - Ordinary Shares

$7.00BUSDP/E 109.9

HIMS

Hims & Hers Health, Inc. Class A Common Stock

$6.77BUSD

LNTH

Lantheus Holdings, Inc. - Common Stock

$6.53BUSDP/E 23.9

KNSA

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

$5.83BUSDP/E 76.6

HIK

Hikma Pharmaceuticals PLC

$4.19BUSDP/E 11.9

Key Statistics

Company

Market Cap50.27M USD

Enterprise Value29.49M USD

Revenue (TTM)1.60M USD

Gross Profit734.61K USD

Net Income (TTM)-2.61M USD

Revenue/Share0.36 SEK

Last Price11.14 SEK

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees5

CountrySE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-55.00

PEG—

EV/EBITDA-15.50

EV/Revenue18.39

P/S30.96

P/B0.56

EPS (TTM)-0.46

EPS (Forward)-0.20

52W Range

7.53055% of range14.12

52W High14.12 SEK

52W Low7.530 SEK

Profitability

Gross Margin56.73%

Oper. Margin-81.95%

EBITDA Margin-118.69%

Profit Margin-201.18%

ROE-4.09%

ROA-3.99%

Growth

Revenue Growth60.30%

Earnings Growth—

Cash Flow & Leverage

Operating CF-1.67M USD

CapEx (TTM)4.13M USD

FCF Margin-256.11%

FCF Yield-8.17%

Net Debt-20.15M USD

Net Debt/EBITDA10.59

Balance Sheet

Debt/Equity0.00

Current Ratio12.26

Quick Ratio12.05

Book Value/Sh19.53 SEK

Cash/Share4.50 SEK

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 SEK

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div DateNov 4, 2019

Pay Date—

Splits

Last Split1:10

Split DateMay 24, 2023

Analyst Consensus

Rating—

Target (Mean)16.00 SEK

Upside (mean)+43.6%

Target Range16.00 SEK – 16.00 SEK

# Analysts1

Ownership

Shares Out.47.18M

Float37.63M

Insiders10.91%

Institutions27.19%

Technical

SMA 5010.67 (+4.4%)

SMA 20010.23 (+8.9%)

Beta1.09

S&P 52W Chg13.94%

Avg Vol (30d)52.38K

Avg Vol (10d)59.37K

Technical Indicators

RSI (14)52.9

MACD0.1092

MACD Signal0.1203

MACD Hist.-0.0112

BB Upper11.45 SEK

BB Middle11.02 SEK

BB Lower10.58 SEK

BB Width7.91%

ATR (14)0.4420 SEK

Vol Ratio (20d)0.35x